15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for ORMP yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $4.17 current
Highest Target—
Average Target—
Lowest Target—
ORMP analyst recommendation trends
86420
Jul
Aug
Strong BuyBuyHoldSellStrong Sell
RATING
JUL
AUG
Strong Buy
0
0
Buy
0
0
Hold
1
1
Sell
0
0
Strong Sell
0
0
Total
1
1
As of Aug, 0 of 1 firms rate ORMP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ORMP EPS & revenue forecast
EPS · NEXT QUARTER
$0.52
Range $0.52 – $0.52 · 1 analysts · -54% YoY
Next period, 1 analysts expect Oramed Pharmaceuticals Inc to earn $0.52 a share (range $0.52 – $0.52), versus $1.13 a year earlier. Full-year consensus is $2.31.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oramed Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORMP.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Hold
No targeton ORMP
Overall win rate
37%
+ Follow
ORMP stock forecast FAQ
Who is the most accurate analyst covering ORMP?+
Among analysts who currently cover ORMP, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #249). Their current call is Hold.
What is Oramed Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.52 per share (range $0.52 – $0.52) across 1 analysts. Full-year EPS is projected at $2.31, rising to — the following year.
How much revenue is Oramed Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ORMP lately?+
As of Aug, 0 of 1 firms rate ORMP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORMP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
